Results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
QOL I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
analyzing I-Claim
QOL I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim

Patients O
with O
breast O
cancer O
reporting O
treatment-induced O
menopausal O
symptoms O
( O
N=422 O
) O
were O
randomly O
assigned O
to O
CBT O
( O
n=109 O
) O
, O
PE O
( O
n=104 O
) O
, O
CBT/PE O
( O
n=106 O
) O
, O
or O
to O
a O
waiting O
list O
control O
group O
( O
n=103 O
) O
. O

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

Quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
Functional O
Living O
Index-Cancer O
( O
FLIC O
) O
, O
Rand O
Functional O
Limitations O
Scale O
, O
Rand O
Mental O
Health O
Inventory O
( O
MHI O
) O
, O
the O
Body O
Image O
Subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O

The O
main O
outcome O
measures O
were O
the O
unmet O
supportive O
care O
needs O
, O
health O
service O
utilization O
, O
and O
quality O
of O
life O
at O
1 O
, O
3 O
, O
and O
6 O
months O
postdischarge O
. O

A O
prospective O
randomized O
clinical O
study O
on O
the O
treatment O
of O
patients O
with O
resectable O
and O
unresectable O
pancreatic O
cancer O
was O
conducted O
at O
the O
Department O
of O
Oncology O
of O
Kaunas O
University O
of O
Medicine O
Hospital O
, O
and O
in O
this O
study O
, O
quality O
of O
life O
was O
analyzed O
. O

Prior O
studies O
have O
suggested O
that O
melatonin O
, O
a O
frequently O
used O
integrative O
medicine O
, O
can O
attenuate O
weight O
loss O
, O
anorexia O
, O
and O
fatigue O
in O
patients O
with O
cancer O
. O

During B-Claim
radiotherapy I-Claim
, I-Claim
both I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
";" I-Claim
dietary B-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
or I-Claim
higher I-Claim
benefit I-Claim
, I-Claim
whereas I-Claim
even I-Claim
3 I-Claim
months I-Claim
after I-Claim
RT I-Claim
, I-Claim
it I-Claim
was I-Claim
the I-Claim
only I-Claim
method I-Claim
to I-Claim
sustain I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

The O
aim O
of O
the O
study O
is O
to O
demonstrate O
that O
intrapatient O
dose O
escalation O
of O
carboplatin O
would O
improve O
the O
outcome O
in O
ovarian O
cancer O
compared O
with O
flat O
dosing O
. O

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
patients I-Premise
maintained/improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single-item I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
.02 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G3 I-Premise
, I-Premise
QoL I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

Percentage B-Premise
transfused I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
SOC I-Premise
( I-Premise
8.6 I-Premise
% I-Premise
v I-Premise
22.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median O
age O
was O
72 O
years O
( O
range O
, O
70-82 O
years O
) O
. O

Exploratory B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
the I-Premise
difference I-Premise
nearly I-Premise
reached I-Premise
significance I-Premise
until I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

Sixty O
female O
breast O
cancer O
survivors O
with O
hot O
flashes O
were O
randomly O
assigned O
to O
receive O
hypnosis O
intervention O
( O
five O
weekly O
sessions O
) O
or O
no O
treatment O
. O

The O
efficacy O
and O
safety O
of O
an O
alternative O
regimen O
that O
does O
not O
show O
significant O
neurotoxicity O
were O
evaluated O
by O
comparing O
gemcitabine-carboplatin O
with O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
in O
a O
Gynecologic O
Cancer O
InterGroup O
trial O
of O
the O
Arbeitsgemeinschaft O
Gynakologische O
Onkologie O
Ovarian O
Cancer O
Study O
Group O
, O
the O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
, O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Gynaecological O
Cancer O
Group O
. O

Repeated O
measures O
MANCOVA O
was O
used O
to O
evaluate O
outcomes O
. O

Outcomes O
were O
reassessed O
6 O
and O
12 O
weeks O
after O
chemotherapy O
started O
. O

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

Menopausal B-Claim
symptoms I-Claim
( I-Claim
e.g. I-Claim
, I-Claim
hot I-Claim
flashes I-Claim
, I-Claim
vaginal I-Claim
dryness I-Claim
, I-Claim
and I-Claim
stress I-Claim
urinary I-Claim
incontinence I-Claim
) I-Claim
are I-Claim
very I-Claim
common I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
managed I-Claim
with I-Claim
standard I-Claim
estrogen I-Claim
replacement I-Claim
therapy I-Claim
( I-Claim
ERT I-Claim
) I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

Hazard O
ratios O
( O
HRs O
) O
with O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
using O
a O
Cox O
proportional O
hazards O
model O
. O

Preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer-related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim

Multicenter O
, O
randomized O
trial O
. O

Patients B-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
had I-Premise
fewer I-Premise
adverse I-Premise
events I-Premise
during I-Premise
chemotherapy I-Premise
related I-Premise
to I-Premise
anorexia I-Premise
and I-Premise
nausea I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Three O
National O
Health O
Service O
oncology O
clinics O
in O
Scotland O
and O
community O
exercise O
facilities O
. O

Fifty O
patients O
were O
randomly O
assigned O
to O
receive O
12 O
weeks O
of O
acupuncture O
( O
n O
= O
25 O
) O
or O
venlafaxine O
( O
n O
= O
25 O
) O
treatment O
. O

The B-Premise
use I-Premise
of I-Premise
IMRT I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Dry B-Premise
mouth I-Premise
and I-Premise
sticky I-Premise
saliva I-Premise
were I-Premise
problems I-Premise
in I-Premise
both I-Premise
groups I-Premise
2 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
. I-Premise

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

In O
a O
controlled O
multicentre O
trial O
, O
patients O
were O
randomised O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
chemotherapy O
. O

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

Patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O

Patients O
with O
various O
malignancies O
participated O
in O
the O
RCT O
( O
n O
= O
210 O
) O
. O

Different B-Claim
treatment I-Claim
modalities I-Claim
consisting I-Claim
of I-Claim
MLD I-Claim
and I-Claim
compression I-Claim
bandage I-Claim
( I-Claim
complex I-Claim
decongestive I-Claim
therapy I-Claim
) I-Claim
or I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
appear I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
LE I-Claim
with I-Claim
similar I-Claim
therapeutic I-Claim
efficacy I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

The O
primary O
endpoint O
was O
the O
difference O
in O
proportion O
of O
patients O
with O
ARSR O
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group/The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG/EORTC O
scale O
) O
at O
follow-up O
. O

Treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0-1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O

Eligible O
patients O
were O
randomized O
to O
receive O
: O
( O
a O
) O
VNR O
25mg/m O
( O
2 O
) O
on O
day O
1 O
, O
8 O
and O
15 O
plus O
CDDP O
100mg/m O
( O
2 O
) O
on O
day O
1 O
every O
4 O
weeks O
or O
( O
b O
) O
VNR O
30 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
8 O
plus O
CDDP O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
. O

Improvements B-Premise
in I-Premise
the I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
of I-Premise
rheumatoid I-Premise
arthritis I-Premise
, I-Premise
physical I-Premise
function I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
observed I-Premise
after I-Premise
6 I-Premise
months I-Premise
, I-Premise
were I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
in I-Premise
this I-Premise
population I-Premise
with I-Premise
difficult-to-treat I-Premise
disease I-Premise
. I-Premise

Dermatology B-Premise
Life I-Premise
Quality I-Premise
Index I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1.95 I-Premise
and I-Premise
1.38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
.20 I-Premise
) I-Premise
. I-Premise

Although O
initial O
pre-trial O
interviews O
revealed O
concerns O
among O
health-care O
professionals O
and O
some O
patients O
regarding O
community O
treatment O
, O
opinions O
were O
largely O
more O
favourable O
in O
post-trial O
interviews O
. O

In B-Premise
the I-Premise
latter I-Premise
patients I-Premise
the I-Premise
received I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
RDI I-Premise
) I-Premise
of I-Premise
cisplatin I-Premise
, I-Premise
adriamycin I-Premise
and I-Premise
etoposide I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
late-alternation I-Premise
arm I-Premise
. I-Premise

High B-Premise
self-assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Between O
March O
2007 O
and O
April O
2010 O
, O
151 O
( O
of O
the O
planned O
534 O
) O
patients O
were O
randomised O
( O
75 O
OSC O
+ O
WBRT O
, O
76 O
OSC O
) O
. O

Different B-Claim
analyses I-Claim
yielded I-Claim
slightly I-Claim
different I-Claim
conclusions I-Claim
but O
, O
in B-Claim
general I-Claim
, I-Claim
the I-Claim
QOL I-Claim
analyses I-Claim
were I-Claim
concordant I-Claim
and I-Claim
showed I-Claim
that I-Claim
patients I-Claim
on I-Claim
DOX I-Claim
alone I-Claim
had I-Claim
fewer I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
related I-Claim
adverse I-Claim
events I-Claim
and I-Claim
better I-Claim
QOL I-Claim
. I-Claim

Adjusted O
linear O
mixed-model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
QoL O
response O
( O
P= O
.005 O
) O
. O

No B-Claim
differences I-Claim
were I-Claim
observed I-Claim
between I-Claim
groups I-Claim
regarding I-Claim
HRQOL I-Claim
at I-Claim
24-month I-Claim
follow-up I-Claim
. I-Claim

Hormone B-Claim
replacement I-Claim
therapy I-Claim
increases I-Claim
cardiovascular I-Claim
and I-Claim
thromboembolic I-Claim
risk I-Claim
when I-Claim
started I-Claim
many I-Claim
years I-Claim
after I-Claim
the I-Claim
menopause I-Claim
. I-Claim

Multilevel O
procedures O
were O
used O
to O
compare O
the O
intervention O
groups O
with O
the O
control O
group O
over O
time O
. O

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
MA I-Premise
( I-Premise
17.1 I-Premise
% I-Premise
v I-Premise
7.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

The O
physiological O
and O
psychological O
stress O
that O
brain O
tumor O
patients O
undergo O
during O
the O
entire O
surgical O
experience O
can O
considerably O
affect O
several O
aspects O
of O
their O
hospitalization O
. O

Even O
though O
both B-Premise
treatment I-Premise
modalities I-Premise
resulted I-Premise
in I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
arm I-Premise
volume I-Premise
( I-Premise
12.2 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
II I-Premise
and I-Premise
14.9 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
I I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
no B-Premise
significant I-Premise
difference I-Premise
( I-Premise
p=0.582 I-Premise
) I-Premise
was I-Premise
found I-Premise
between I-Premise
those I-Premise
two I-Premise
groups I-Premise
. I-Premise

Patients O
in O
the O
control O
arm O
received O
radiotherapy O
only O
. O

This O
multicenter O
, O
open-label O
, O
phase O
III O
study O
randomly O
assigned O
patients O
in O
a O
1:2 O
ratio O
to O
irinotecan O
given O
either O
weekly O
( O
125 O
mg/m O
( O
2 O
) O
) O
or O
once O
every O
3 O
weeks O
( O
350 O
mg/m O
( O
2 O
) O
, O
or O
300 O
mg/m O
( O
2 O
) O
in O
patients O
who O
were O
> O
/= O
70 O
years O
of O
age O
, O
who O
had O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
equal O
to O
2 O
, O
or O
who O
had O
prior O
pelvic O
irradiation O
) O
. O

Biomarker O
expression O
was O
assessed O
by O
immunohistochemistry O
. O

Acupuncture B-Claim
appears I-Claim
to I-Claim
be I-Claim
equivalent I-Claim
to I-Claim
drug I-Claim
therapy I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

The B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.23 I-Premise
to I-Premise
0.60 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.27 I-Premise
to I-Premise
0.50 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow-up O
was O
22·2 O
months O
( O
IQR O
20·2-24·8 O
) O
. O

Percentages O
of O
patients O
completing O
9 O
months O
of O
treatment O
in O
the O
PCV O
, O
TMZ-5 O
, O
and O
TMZ-21 O
arms O
were O
17 O
% O
, O
26 O
% O
, O
and O
13 O
% O
, O
respectively O
. O

The O
second O
International O
Society O
of O
Paediatric O
Oncology O
( O
SIOP O
) O
study O
for O
rhabdomyosarcoma O
( O
MMT84 O
) O
had O
several O
goals O
. O

Vinorelbine B-Claim
improves I-Claim
survival I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
possibly I-Claim
improves I-Claim
overall I-Claim
QoL I-Claim
. I-Claim

The O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O

Exercise O
therapies O
were O
performed O
for O
one O
session O
per O
week O
for O
eight O
weeks O
. O

The B-Premise
differences I-Premise
in I-Premise
tumor I-Premise
response I-Premise
( I-Premise
35.5 I-Premise
and I-Premise
46.5 I-Premise
% I-Premise
for I-Premise
GE I-Premise
and I-Premise
GP I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
. I-Premise

A O
total O
of O
72 O
NSCLC O
study O
subjects O
with O
MPE O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O

Sertraline B-Premise
was I-Premise
discontinued I-Premise
more I-Premise
often I-Premise
and I-Premise
earlier I-Premise
than I-Premise
was I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
1.46 I-Premise
[ I-Premise
1.03-2.06 I-Premise
] I-Premise
, I-Premise
p=0.03 I-Premise
) I-Premise
. I-Premise

Nineteen B-Premise
percent I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
were I-Premise
progression-free I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
compared I-Premise
with I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
alone I-Premise
( I-Premise
P I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Patients O
' O
quality O
of O
life O
was O
evaluated O
with O
the O
Cardiff O
Wound O
Impact O
Schedule O
( O
CWIS O
) O
. O

This O
study O
examined O
whether O
changes O
in O
self-efficacy O
explain O
the O
effects O
of O
a O
mailed O
print O
intervention O
on O
long-term O
dietary O
practices O
of O
breast O
and O
prostate O
cancer O
survivors O
. O

The O
mean O
number O
of O
hot O
flashes O
per O
day O
was O
reduced O
from O
8.7 O
( O
standard O
deviation O
[ O
SD O
] O
, O
3.9 O
) O
to O
6.2 O
( O
SD O
, O
4.2 O
) O
in O
the O
TRUE O
acupuncture O
group O
and O
from O
10.0 O
( O
SD O
, O
6.1 O
) O
to O
7.6 O
( O
SD O
, O
5.7 O
) O
in O
the O
sham O
group O
. O

Thalidomide O
with O
melphalan/prednisone O
( O
MPT O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
MM O
) O
based O
on O
five O
randomized O
trials O
. O

To O
evaluate O
the O
safety O
and O
efficacy O
of O
abatacept O
during O
2 O
years O
of O
the O
ATTAIN O
( O
Abatacept O
Trial O
in O
Treatment O
of O
Anti-TNF O
INadequate O
responders O
) O
trial O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Results O
Baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O

Univariate O
Kaplan O
Meier O
survival O
analysis O
and O
log O
rank O
tests O
were O
used O
to O
compare O
the O
risk O
of O
progression O
. O

Secondary O
outcomes O
were O
role O
and O
emotional O
functioning O
and O
feelings O
of O
control O
and O
anxiety O
. O

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

Patients O
received O
LV O
200 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
followed O
by O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolus O
) O
and O
FU O
600 O
mg/m O
( O
2 O
) O
( O
22-hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
LV5FU2 O
";" O
arm O
A O
) O
, O
LV5FU2 O
plus O
cisplatin O
50 O
mg/m O
( O
2 O
) O
( O
1-hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
B O
) O
, O
or O
LV5FU2 O
plus O
irinotecan O
180 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
on O
day O
1 O
( O
arm O
C O
) O
. O

To O
compare O
in O
a O
phase O
III O
study O
the O
safety O
and O
efficacy O
of O
fludarabine O
to O
that O
of O
cyclophosphamide O
, O
vincristine O
, O
and O
prednisone O
( O
CVP O
) O
in O
recurrent O
, O
low-grade O
, O
non-Hodgkin O
's O
lymphoma O
after O
previous O
response O
to O
systemic O
treatment O
. O

Patients B-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
( I-Premise
TOI I-Premise
) I-Premise
scores I-Premise
( I-Premise
physical I-Premise
well-being I-Premise
, I-Premise
functional I-Premise
well-being I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
concerns I-Premise
subscales I-Premise
in I-Premise
FACT-B+4 I-Premise
) I-Premise
and I-Premise
recovered I-Premise
more I-Premise
slowly I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
SNB I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In O
total O
, O
126 O
patients O
from O
East O
and O
South-East O
Asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent-to-treat O
population O
) O
: O
88 O
from O
Korea O
, O
28 O
from O
China O
and O
10 O
from O
Malaysia O
";" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
Indian O
ethnicity O
. O

Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19.5 I-Premise
% I-Premise
vs. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
was I-Premise
321 I-Premise
days I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
was I-Premise
not I-Premise
reached I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
363 I-Premise
days I-Premise
for I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.491 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
. I-Premise

The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Analysis B-Premise
of I-Premise
the I-Premise
trial I-Premise
group I-Premise
demonstrated I-Premise
a I-Premise
significant I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
in I-Premise
body I-Premise
weight I-Premise
( I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

The O
majority O
of O
pain O
topics O
had O
to O
be O
discussed O
. O

This O
study O
was O
designed O
to O
evaluate O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
of O
combination O
of O
chemotherapy O
drugs O
and O
intraperitoneal O
perfusion O
of O
verapamil O
in O
the O
treatment O
of O
malignant O
ascites O
. O

At O
six O
oncology O
clinics O
, O
physicians O
( O
N=22 O
) O
and O
nurses O
( O
N=23 O
) O
enrolled O
patients O
( O
N=93 O
) O
who O
were O
over O
18 O
years O
of O
age O
, O
with O
cancer O
diagnoses O
, O
pain O
, O
and O
a O
life O
expectancy O
of O
at O
least O
6 O
months O
. O

Our O
primary O
end O
point O
was O
patient-rated O
physical O
functioning O
assessed O
by O
the O
Trial O
Outcome O
Index-Anemia O
. O

In O
the O
delayed O
treatment O
group O
, O
48/115 O
( O
42 O
% O
) O
patients O
received O
thoracic O
radiotherapy O
( O
29 O
received O
one O
of O
the O
recommended O
regimens O
) O
";" O
64 O
( O
56 O
% O
) O
died O
without O
receiving O
thoracic O
radiotherapy O
";" O
the O
remaining O
three O
( O
3 O
% O
) O
were O
alive O
at O
the O
end O
of O
the O
study O
without O
having O
received O
the O
treatment O
. O

Mean O
scores O
of O
individual O
domains/scales O
of O
3D-CRT O
and O
IMRT O
were O
compared O
using O
't O
' O
test O
at O
each O
time O
point O
";" O
while O
longitudinal O
change O
in O
mean O
scores O
of O
both O
groups O
over O
time O
was O
evaluated O
by O
repeated O
measurement O
analysis O
of O
variance O
. O

An O
overall O
intent-to-treat O
analysis O
was O
performed O
. O

At B-Premise
20 I-Premise
wk I-Premise
, I-Premise
4 I-Premise
wk I-Premise
after I-Premise
planned I-Premise
interruption I-Premise
of I-Premise
duloxetine I-Premise
, I-Premise
we I-Premise
observed I-Premise
a I-Premise
U-turn I-Premise
, I-Premise
23 I-Premise
patients I-Premise
were I-Premise
completely I-Premise
dry I-Premise
in I-Premise
group I-Premise
A I-Premise
versus I-Premise
38 I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
decreased I-Premise
during I-Premise
the I-Premise
first I-Premise
8 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
, I-Premise
and I-Premise
a I-Premise
partial I-Premise
recovery I-Premise
followed I-Premise
. I-Premise

Linear B-Premise
mixed I-Premise
models I-Premise
( I-Premise
primary I-Premise
model I-Premise
) I-Premise
demonstrated I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
overall I-Premise
difference I-Premise
between I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
and I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
for I-Premise
QL2 I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-1.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-4.61 I-Premise
, I-Premise
0.78 I-Premise
) I-Premise
, I-Premise
BRBS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.18 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.98 I-Premise
, I-Premise
1.62 I-Premise
) I-Premise
, I-Premise
or I-Premise
BRAS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.94 I-Premise
, I-Premise
2.10 I-Premise
) I-Premise
. I-Premise

Our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
TRT I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
HRQOL I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short-term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

The B-Premise
disease-related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

We O
aimed O
to O
assess O
quality O
of O
life O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
in O
an O
open-label O
phase O
III O
randomised O
comparison O
between O
lifelong O
endocrine O
treatment O
with O
and O
without O
radiotherapy O
. O

At B-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
AET I-Premise
was I-Premise
still I-Premise
borderline I-Premise
or I-Premise
significantly I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.054 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
, I-Premise
and I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
without I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
disease I-Premise
recurrence/progression I-Premise
. I-Premise

Continence O
scoring O
, O
anorectal O
manometry O
, O
and O
endoanal O
ultrasound O
assessments O
were O
made O
before O
surgery O
. O

Outcomes B-Premise
in I-Premise
the I-Premise
nurse I-Premise
group I-Premise
were I-Premise
not I-Premise
inferior I-Premise
to I-Premise
outcomes I-Premise
in I-Premise
the I-Premise
gastroenterologist I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
1·36 I-Premise
, I-Premise
one I-Premise
sided I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1·48 I-Premise
) I-Premise
. I-Premise

To O
explore O
the O
role O
of O
monochemotherapy O
, O
the O
authors O
evaluated O
5-fluorouracil O
( O
5-FU O
) O
, O
modulated O
by O
6S-leucovorin O
( O
6S-LV O
) O
and O
a O
cisplatin-containing O
regimen O
, O
which O
was O
comprised O
of O
epirubicin O
, O
etoposide O
, O
and O
cisplatin O
with O
the O
addition O
of O
the O
reversal O
agent O
lonidamine O
( O
EEP-L O
) O
. O

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
8.5 I-Premise
months I-Premise
, I-Premise
and I-Premise
8.0 I-Premise
months I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
. I-Premise

One-year B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
FU I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
FUP I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

HEC O
participants O
received O
nutritional O
information O
and O
equal O
attention O
. O

Increased O
attention O
has O
focused O
on O
exercise O
as O
a O
quality O
of O
life O
intervention O
for O
breast O
cancer O
survivors O
during O
and O
after O
adjuvant O
therapy O
. O

Both B-Claim
measures I-Claim
were I-Claim
responsive I-Claim
";" I-Claim
out B-Premise
of I-Premise
24 I-Premise
changes I-Premise
over I-Premise
time I-Premise
, I-Premise
19 I-Premise
were I-Premise
in I-Premise
the I-Premise
expected I-Premise
direction I-Premise
for I-Premise
the I-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
for I-Premise
9 I-Premise
of I-Premise
19 I-Premise
) I-Premise
and I-Premise
17 I-Premise
for I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
for I-Premise
10 I-Premise
of I-Premise
17 I-Premise
) I-Premise
. I-Premise

A O
randomized O
Phase O
III O
trial O
for O
Stage O
IIIA O
( O
T1-T3N2M0 O
) O
non-small O
cell O
lung O
cancer O
was O
conducted O
by O
the O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
and O
Eastern O
Cooperative O
Oncology O
Group O
between O
April O
1990 O
and O
April O
1994 O
. O

Fibroid B-Premise
infarction I-Premise
at I-Premise
6 I-Premise
months I-Premise
was I-Premise
complete I-Premise
in I-Premise
35 I-Premise
% I-Premise
of I-Premise
women I-Premise
, I-Premise
almost I-Premise
complete I-Premise
in I-Premise
29 I-Premise
% I-Premise
, I-Premise
and I-Premise
partial I-Premise
in I-Premise
36 I-Premise
% I-Premise
. I-Premise

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT-B I-Premise
and I-Premise
FACT-G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.40 I-Premise
to I-Premise
5.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2.8 I-Premise
to I-Premise
5.1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

No O
patient O
received O
hormonal O
therapy O
. O

At B-Premise
study I-Premise
completion I-Premise
, I-Premise
participants I-Premise
in I-Premise
the I-Premise
IG I-Premise
were I-Premise
walking I-Premise
twice I-Premise
as I-Premise
far I-Premise
and I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
continued I-Premise
walking I-Premise
or I-Premise
another I-Premise
form I-Premise
of I-Premise
exercise I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
UCG I-Premise
. I-Premise

Quality O
of O
life O
assessments O
were O
performed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-OES24 O
modules O
. O

Median B-Premise
PFS I-Premise
was I-Premise
5.5 I-Premise
months I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.04 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.727 I-Premise
) I-Premise
, I-Premise
while I-Premise
ORR I-Premise
was I-Premise
25 I-Premise
% I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
. I-Premise

The O
patients O
were O
randomized O
to O
either O
daunomycin-cytosine O
arabinoside O
( O
control O
arm O
: O
n O
= O
161 O
) O
or O
daunomycin-cytosine O
arabinoside O
with O
GM-CSF O
( O
GM-CSF O
arm O
: O
n O
= O
157 O
) O
. O

Time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR=0.61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.42-0.88 I-Premise
] I-Premise
";" I-Premise
p=0.0080 I-Premise
and I-Premise
HR=0.66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.46-0.94 I-Premise
] I-Premise
";" I-Premise
p=0.0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

This O
phase O
2 O
, O
25-week O
, O
open-label O
study O
evaluated O
the O
noninferiority O
of O
darbepoetin O
alfa O
administered O
weekly O
vs. O
as O
an O
extended O
dosing O
schedule O
( O
every O
2 O
or O
3 O
weeks O
) O
in O
patients O
with O
CIA O
. O

Between O
1999 O
and O
2002 O
, O
83 O
patients O
were O
recruited O
into O
the O
study O
at O
Westmead O
and O
Nepean O
Hospitals O
, O
Sydney O
. O

Despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
GJJ B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long-term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
for I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
, I-Premise
which I-Premise
was I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise

In B-Premise
response I-Premise
to I-Premise
training I-Premise
, I-Premise
QOL I-Premise
, I-Premise
VO2peak I-Premise
( I-Premise
mean I-Premise
3.9 I-Premise
ml/kg/min I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
, I-Premise
6.90 I-Premise
) I-Premise
performance I-Premise
in I-Premise
leg I-Premise
press I-Premise
( I-Premise
17.9 I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.8 I-Premise
, I-Premise
22.4 I-Premise
) I-Premise
and I-Premise
sit-stand I-Premise
test I-Premise
( I-Premise
- I-Premise
0.67 I-Premise
s I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0.52 I-Premise
, I-Premise
- I-Premise
1.2 I-Premise
) I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+15·2 I-Premise
, I-Premise
1·3 I-Premise
to I-Premise
29·1 I-Premise
, I-Premise
P=0.033 I-Premise
) I-Premise
. I-Premise

Patients O
were O
randomized O
1:1 O
to O
an O
extended O
dosing O
schedule O
( O
EDS O
: O
darbepoetin O
alfa O
300 O
μg O
Q2W O
if O
chemotherapy O
was O
QW O
, O
Q2W O
, O
or O
Q4W O
or O
darbepoetin O
alfa O
500 O
μg O
Q3W O
if O
chemotherapy O
was O
Q3W O
) O
or O
weekly O
( O
150 O
μg O
QW O
regardless O
of O
chemotherapy O
schedule O
) O
. O

Four O
hundred O
eighty-six O
patients O
with O
recurrent O
SCCHN O
were O
randomly O
assigned O
to O
oral O
gefitinib O
250 O
mg/day O
, O
gefitinib O
500 O
mg/day O
, O
or O
methotrexate O
40 O
mg/m O
( O
2 O
) O
intravenously O
weekly O
. O

A O
total O
of O
243 O
patients O
with O
stage O
II O
to O
IIIA/B O
non-small-cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
AUC O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg/m O
( O
2 O
) O
IV O
) O
and O
carboplatin O
( O
AUC O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69.6 O
Gy O
at O
1.2 O
Gy O
bid O
) O
. O

All O
had O
chemotherapy O
. O

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
was I-Premise
frequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
febrile I-Premise
neutropenia I-Premise
and I-Premise
infections I-Premise
were I-Premise
more I-Premise
frequent I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
respectively I-Premise
, I-Premise
33 I-Premise
% I-Premise
v I-Premise
10 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
8 I-Premise
% I-Premise
v I-Premise
2 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

After B-Premise
16 I-Premise
wk I-Premise
, I-Premise
39 I-Premise
patients I-Premise
versus I-Premise
27 I-Premise
were I-Premise
dry I-Premise
( I-Premise
p=0.007 I-Premise
) I-Premise
. I-Premise

The B-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
subscale I-Premise
was I-Premise
associated I-Premise
with I-Premise
all I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
( I-Premise
r=-0.45 I-Premise
to I-Premise
-0.70 I-Premise
, I-Premise
all I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Between O
February O
1999 O
and O
August O
2001 O
, O
422 O
patients O
( O
GCa O
, O
n O
= O
212 O
";" O
MIC O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
United O
Kingdom O
. O

Median B-Premise
survival I-Premise
times I-Premise
were I-Premise
29 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
versus I-Premise
11 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
28 I-Premise
% I-Premise
versus I-Premise
8 I-Premise
% I-Premise
. I-Premise

EORTC O
QLQ-C30 O
scores O
were O
evaluated O
among O
patients O
with O
a O
valid O
baseline O
and O
at O
least O
one O
post-baseline O
HRQoL O
assessment O
. O

Patients O
were O
randomized O
to O
receive O
MVP O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Cisplatin O
100 O
mg/m2 O
d1 O
) O
or O
MVC O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Carboplatin O
300 O
mg/m2 O
d1 O
) O
every O
3 O
weeks O
. O

Energy B-Premise
intake I-Premise
after I-Premise
RT I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

All O
studies O
on O
SLN O
biopsy O
in O
breast O
cancer O
report O
a O
variable O
FALSE O
negative O
rate O
, O
whose O
prognostic O
consequences O
are O
still O
unclear O
. O

Complications O
, O
drainage O
time O
, O
hospital O
stay O
, O
and O
quality O
of O
life O
( O
Medical O
Outcomes O
Study O
36-item O
short O
form O
and O
World O
Health O
Organization O
quality-of-life O
questionnaires O
) O
were O
also O
analyzed O
. O

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Regression O
analysis O
was O
used O
to O
analyze O
the O
impact O
on O
outcome O
of O
baseline O
factors O
( O
other O
than O
type O
of O
embolic O
agent O
) O
. O

LV5FU2 O
with O
high-dose O
leucovorin O
( O
LV O
) O
, O
weekly O
infusional O
5-fluorouracil O
( O
5FU O
) O
( O
AIO O
schedule O
) O
and O
raltitrexed O
have O
been O
demonstrated O
to O
be O
active O
agents O
in O
first-line O
treatment O
of O
colorectal O
cancer O
. O

Although B-Premise
a I-Premise
dosage I-Premise
of I-Premise
50 I-Premise
mg I-Premise
of I-Premise
bicalutamide I-Premise
once I-Premise
daily I-Premise
was I-Premise
not I-Premise
as I-Premise
effective I-Premise
as I-Premise
castration I-Premise
, I-Premise
the B-Claim
favorable I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
and I-Claim
the I-Claim
low I-Claim
incidence I-Claim
of I-Claim
nonhormonal I-Claim
adverse I-Claim
events I-Claim
provide I-Claim
reasons I-Claim
to I-Claim
evaluate I-Claim
bicalutamide I-Claim
, I-Claim
as I-Claim
a I-Claim
single I-Claim
therapeutic I-Claim
agent I-Claim
, I-Claim
at I-Claim
higher I-Claim
doses I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
differences I-Claim
in I-Claim
acute I-Claim
toxicities I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim

Improvement B-Premise
was I-Premise
noted I-Premise
in I-Premise
physical I-Premise
capacity I-Premise
: I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
for I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
was I-Premise
0.16 I-Premise
l/min I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.1 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
( I-Premise
leg I-Premise
press I-Premise
) I-Premise
was I-Premise
29.7 I-Premise
kg I-Premise
( I-Premise
23.4 I-Premise
to I-Premise
34.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT-I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

The B-Premise
addition I-Premise
of I-Premise
RT I-Premise
to I-Premise
surgery I-Premise
resulted I-Premise
in I-Premise
more I-Premise
frequent I-Premise
urination I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
early I-Premise
report I-Premise
of I-Premise
more I-Premise
bowel I-Premise
dysfunction I-Premise
, O
although B-Premise
bowel I-Premise
function I-Premise
differences I-Premise
disappeared I-Premise
over I-Premise
the I-Premise
5-year I-Premise
period I-Premise
. I-Premise

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

Weight O
, O
the O
Schwartz O
Fatigue O
Scale O
, O
and O
the O
Spitzer O
Quality O
of O
Life O
Scale O
were O
also O
measured O
. O

All B-Premise
95 I-Premise
% I-Premise
confidence I-Premise
intervals I-Premise
for I-Premise
the I-Premise
differences I-Premise
were I-Premise
within I-Premise
±10 I-Premise
percentage I-Premise
points I-Premise
, I-Premise
indicating I-Premise
noninferiority I-Premise
. I-Premise

The O
documented O
administration O
of O
postoperative O
pain O
medications O
";" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
BCAA O
granules O
, O
given O
nocturnally O
, O
in O
improving O
QOL O
in O
these O
patients O
. O

Additional B-Claim
studies I-Claim
are I-Claim
warranted I-Claim
. I-Claim

Patients O
completed O
the O
Short O
Form O
36-item O
Health O
Survey O
( O
SF-36 O
) O
and O
the O
Menopause O
Specific O
Quality O
of O
Life O
Questionnaire O
( O
MENQOL O
) O
at O
baseline O
, O
6 O
months O
, O
and O
annually O
. O

Patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy-induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim

Patients B-Premise
who I-Premise
experienced I-Premise
more I-Premise
concentration I-Premise
and I-Premise
memory I-Premise
problems I-Premise
at I-Premise
T1 I-Premise
benefited I-Premise
more I-Premise
from I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
and I-Premise
are I-Premise
indicators I-Premise
. I-Premise

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
0.2-13.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
patients I-Premise
frequently I-Premise
used I-Premise
the I-Premise
CCSP I-Premise
to I-Premise
manage I-Premise
psychological I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
severe I-Premise
ARSR I-Premise
between I-Premise
the I-Premise
groups I-Premise
at I-Premise
any I-Premise
point I-Premise
of I-Premise
assessment I-Premise
. I-Premise

Chemotherapy O
was O
first-line O
or O
second-line O
for O
MBC O
. O

Maintenance B-Premise
therapy I-Premise
with I-Premise
erlotinib I-Premise
did I-Premise
not I-Premise
impact I-Premise
on I-Premise
deterioration I-Premise
in I-Premise
HRQoL I-Premise
: I-Premise
TSP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
=0.91 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.74-1.12 I-Premise
] I-Premise
";" I-Premise
n=785 I-Premise
) I-Premise
, I-Premise
TTD I-Premise
in I-Premise
TOI I-Premise
( I-Premise
HR=1.06 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.87-1.31 I-Premise
] I-Premise
";" I-Premise
n=781 I-Premise
) I-Premise
and I-Premise
TTD I-Premise
in I-Premise
HRQoL I-Premise
( I-Premise
HR=0.96 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.79-1.16 I-Premise
] I-Premise
";" I-Premise
n=776 I-Premise
) I-Premise
. I-Premise

GEM B-Claim
does I-Claim
not I-Claim
provide I-Claim
an I-Claim
advantage I-Claim
compared I-Claim
with I-Claim
PLD I-Claim
in I-Claim
terms I-Claim
of I-Claim
TTP I-Claim
in I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
experience I-Claim
recurrence I-Claim
within I-Claim
12 I-Claim
months I-Claim
after I-Claim
primary I-Claim
treatment I-Claim
but I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
spectrum I-Claim
of I-Claim
drugs I-Claim
to I-Claim
be I-Claim
possibly I-Claim
used I-Claim
in I-Claim
the I-Claim
salvage I-Claim
setting I-Claim
. I-Claim

In O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
indicate I-Claim
that I-Claim
patients I-Claim
with I-Claim
gastrointestinal I-Claim
cancer I-Claim
, I-Claim
who I-Claim
undergo I-Claim
surgery I-Claim
for I-Claim
stomach I-Claim
, I-Claim
pancreatic I-Claim
, I-Claim
primary I-Claim
liver I-Claim
, I-Claim
or I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
benefit I-Claim
from I-Claim
a I-Claim
formal I-Claim
program I-Claim
of I-Claim
psychotherapeutic I-Claim
support I-Claim
during I-Claim
the I-Claim
inpatient I-Claim
hospital I-Claim
stay I-Claim
in I-Claim
terms I-Claim
of I-Claim
long-term I-Claim
survival I-Claim
. I-Claim

Quality O
of O
life O
was O
assessed O
from O
the O
responses O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire O
( O
C30 O
, O
health O
status O
and O
lung O
cancer O
module O
13 O
) O
. O

Survival B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.70 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
arm I-Premise
. I-Premise

In O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O

According O
to O
the O
design O
criteria O
, O
palliation O
was O
equivalent O
between O
the O
two O
arms O
. O

Few O
intervention O
studies O
have O
been O
conducted O
to O
help O
couples O
manage O
the O
effects O
of O
prostate O
cancer O
and O
maintain O
their O
quality O
of O
life O
. O

No O
patient O
received O
antiretroviral O
therapy O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
depression I-Premise
associated I-Premise
with I-Premise
IFN5 I-Premise
but I-Premise
no I-Premise
change I-Premise
was I-Premise
noted I-Premise
with I-Premise
IFN1 I-Premise
. I-Premise

Although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
RP O
, O
BT O
, O
or O
random O
assignment O
. O

The B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs. I-Premise
5 I-Premise
days I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

BT O
plans O
were O
revised O
before O
each O
CTX O
and O
30 O
, O
60 O
, O
and O
90 O
days O
after O
the O
last O
CTX O
and O
reinforced O
7 O
to O
9 O
days O
later O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.6 I-Premise
years I-Premise
, I-Premise
results I-Premise
for I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
and I-Premise
Sx I-Premise
yielded I-Premise
similar I-Premise
DFS I-Premise
( I-Premise
6-year I-Premise
DFS I-Premise
, I-Premise
67 I-Premise
% I-Premise
v I-Premise
66 I-Premise
% I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.06 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.69 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
6-year I-Premise
OS I-Premise
, I-Premise
75 I-Premise
% I-Premise
v I-Premise
73 I-Premise
% I-Premise
";" I-Premise
HR I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.76 I-Premise
to I-Premise
1.46 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.77 I-Premise
) I-Premise
. I-Premise

To O
determine O
whether O
weekly O
epoetin O
alfa O
could O
improve O
hemoglobin O
( O
HgB O
) O
levels O
, O
reduce O
RBC O
transfusions O
, O
and O
improve O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
advanced O
cancer O
and O
with O
anemia O
after O
receiving O
myelosuppressive O
chemotherapy O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
impact O
on O
QoL O
, O
substituting O
cisplatin O
, O
a O
pivot O
drug O
in O
NSCLC O
therapy O
, O
with O
carboplatin O
, O
an O
analogue O
with O
an O
improved O
toxicity O
profile O
. O

Similarly B-Premise
, I-Premise
ASES I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
Group I-Premise
I I-Premise
and I-Premise
II I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

This O
study O
included O
three O
groups O
of O
patients O
, O
enrolled O
consecutively O
. O

The O
primary O
end O
point O
was O
time-to-progression O
( O
TTP O
) O
. O

We B-Claim
can I-Claim
not I-Claim
exclude I-Claim
the I-Claim
possibility I-Claim
that I-Claim
a I-Claim
longer I-Claim
and I-Claim
more I-Claim
intense I-Claim
acupuncture I-Claim
intervention I-Claim
could I-Claim
produce I-Claim
a I-Claim
larger I-Claim
reduction I-Claim
of I-Claim
these I-Claim
symptoms I-Claim
. I-Claim

Complete O
remission O
rates O
before O
random O
assignment O
were O
11 O
% O
for O
those O
receiving O
HDCT O
and O
12 O
% O
for O
those O
receiving O
ST. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
48 I-Premise
months I-Premise
, I-Premise
79 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
and I-Premise
77 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
ST I-Premise
arm I-Premise
";" I-Premise
seven B-Premise
patients I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
died I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
toxicity I-Premise
. I-Premise

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
mean I-Premise
dysphagia I-Premise
grade I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
( I-Premise
P=0.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
worse I-Premise
swallowing I-Premise
reported I-Premise
by I-Premise
rigid I-Premise
stent-treated I-Premise
patients I-Premise
( I-Premise
mean I-Premise
dysphagia I-Premise
score I-Premise
difference=-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-0.10 I-Premise
to I-Premise
-0.89 I-Premise
, I-Premise
P=0.014 I-Premise
) I-Premise
. I-Premise

PVI B-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3/4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

Sixteen O
subjects O
were O
randomly O
assigned O
to O
either O
a O
training O
( O
n O
= O
8 O
";" O
age O
: O
50 O
+/- O
5 O
yrs O
) O
or O
control O
non-exercising O
group O
( O
n O
= O
8 O
";" O
age O
: O
51 O
+/- O
10 O
yrs O
) O
. O

Patients O
receiving O
adjuvant O
RT O
reported O
worse O
bowel O
function O
( O
through O
approximately O
2 O
years O
) O
and O
worse O
urinary O
function O
. O

The O
randomized O
, O
controlled O
BOLERO-2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression-free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
EVE O
+ O
EXE O
) O
versus O
placebo O
plus O
exemestane O
( O
PBO O
+ O
EXE O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O

AET B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient-rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2-irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

The O
maximum O
incidence O
of O
dysuria O
was O
85 O
% O
at O
1 O
month O
after O
brachytherapy O
, O
with O
subsequent O
resolution O
over O
time O
. O

Among B-Claim
patients I-Claim
with I-Claim
painful I-Claim
chemotherapy-induced I-Claim
peripheral I-Claim
neuropathy I-Claim
, I-Claim
the I-Claim
use I-Claim
of I-Claim
duloxetine I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
for I-Claim
5 I-Claim
weeks I-Claim
resulted I-Claim
in I-Claim
a I-Claim
greater I-Claim
reduction I-Claim
in I-Claim
pain I-Claim
. I-Claim

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

Pemetrexed O
maintenance O
therapy O
significantly O
improved O
overall O
survival O
and O
progression-free O
survival O
compared O
with O
placebo O
, O
and O
had O
a O
good O
safety O
profile O
in O
a O
phase O
3 O
placebo-controlled O
study O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

A O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stages O
IIB-IV O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
TC-Top O
";" O
658 O
patients O
) O
or O
surveillance O
( O
TC O
";" O
650 O
patients O
) O
on O
a O
3-week O
per O
cycle O
schedule O
. O

The B-Premise
15-year I-Premise
actuarial I-Premise
locoregional I-Premise
recurrence I-Premise
rates I-Premise
were I-Premise
5.8 I-Premise
% I-Premise
for I-Premise
EBRT I-Premise
versus I-Premise
15.5 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
15-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
versus I-Premise
60 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.14 I-Premise
) I-Premise
. I-Premise

Time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
QOL O
were O
secondary O
end O
points O
. O

The O
aim O
of O
the O
study O
was O
to O
compare O
clinical O
outcomes O
and O
quality O
of O
life O
in O
patients O
undergoing O
surgery O
for O
pilonidal O
disease O
with O
unroofing O
and O
marsupialization O
( O
UM O
) O
or O
rhomboid O
excision O
and O
Limberg O
flap O
( O
RELP O
) O
procedures O
. O

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

In O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient-tailored O
treatment O
( O
PPT O
) O
of O
symptoms O
or O
care O
as O
usual O
. O

Adult O
patients O
with O
advanced O
cancer O
, O
CACS O
, O
weight O
loss O
( O
> O
or O
= O
5 O
% O
over O
6 O
months O
) O
, O
and O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
performance O
status O
( O
PS O
) O
< O
or O
= O
2 O
were O
randomly O
assigned O
( O
2:2:1 O
) O
to O
receive O
CE O
( O
standardized O
for O
2.5 O
mg O
THC O
and O
1 O
mg O
cannabidiol O
) O
or O
THC O
( O
2.5 O
mg O
) O
or O
PL O
orally O
, O
twice O
daily O
for O
6 O
weeks O
. O

Previously O
untreated O
stage O
III O
to O
IVB O
NPC O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg/m O
( O
2 O
) O
/wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
CRT O
alone O
. O

Eighty O
percent O
of O
patients O
had O
stage O
IV O
NSCLC O
, O
with O
squamous O
cell O
( O
n=21 O
) O
, O
adenocarcinoma O
( O
n=12 O
) O
, O
and O
undifferentiated O
( O
n=7 O
) O
histologies O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

The O
effectiveness O
of O
a O
Pain O
Education O
Program O
in O
cancer O
patients O
with O
chronic O
pain O
offered O
by O
nurses O
was O
investigated O
in O
a O
randomized O
controlled O
clinical O
trial O
. O

In O
addition O
, O
predefined O
AEs O
were O
analyzed O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre-operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

Our O
primary O
sleep O
endpoint O
was O
global O
sleep O
quality O
assessed O
by O
the O
Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
regular O
completion O
of O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
and O
Hospital O
Anxiety O
and O
Depression O
Scale O
with O
feedback O
to O
oncologists O
) O
, O
attention-control O
( O
completion O
of O
same O
questionnaires O
without O
feedback O
) O
, O
and O
control O
( O
standard O
care O
) O
arms O
. O

Before O
and O
after O
the O
intervention O
period O
, O
all O
of O
the O
subjects O
performed O
a O
cardiorespiratory O
test O
to O
measure O
peak O
oxygen O
uptake O
( O
VO2peak O
) O
, O
a O
dynamic O
strength O
endurance O
test O
( O
maximum O
number O
of O
repetitions O
for O
chest O
and O
leg O
press O
exercise O
at O
30 O
- O
35 O
% O
and O
100 O
- O
110 O
% O
of O
body O
mass O
, O
respectively O
) O
and O
a O
sit-stand O
test O
. O

Thirty-nine O
patients O
were O
randomly O
assigned O
to O
CONNECT O
and O
36 O
to O
usual O
care O
. O

